A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

682Citations
Citations of this article
203Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In a phase 2 open-label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed after or were refractory to frontline therapy were randomized to receive intravenous 1.0 or 1.3 mg/m 2 bortezomib twice weekly for 2 weeks, every 3 weeks for a maximum of eight cycles. Dexamethasone was permitted in patients with progressive or stable disease after two or four cycles respectively. Responses were determined using modified European Group for Blood and Marrow Transplantation criteria. The complete response (CR) + partial response (PR) rate for bortezomib alone was 30% [90% confidence interval (CI), 15.7-47.1] and 38% (90% CI, 22.6-56.4) in the 1.0 mg/m2 (8 of 27 patients) and 1.3 mg/m2 (10 of 26 patients) groups respectively. The CR + PR rate for patients who received bortezomib alone or in combination with dexamethasone was 37% and 50% for the 1.0 and 1.3 mg/m2 cohorts respectively. The most common grade 3 adverse events were thrombocytopenia (24%), neutropenia (17%), lymphopenia (11%) and peripheral neuropathy (9%). Grade 4 events were observed in 9% (five of 54 patients). Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.

References Powered by Scopus

A phase 2 study of Bortezomib in relapsed, refractory myeloma

2499Citations
N/AReaders
Get full text

Antitumor activity of thalidomide in refractory multiple myeloma

2472Citations
N/AReaders
Get full text

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation

1508Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

2301Citations
N/AReaders
Get full text

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1713Citations
N/AReaders
Get full text

Targeting apoptosis pathways in cancer therapy

1245Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., … Anderson, K. C. (2004). A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 127(2), 165–172. https://doi.org/10.1111/j.1365-2141.2004.05188.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 65

57%

Researcher 32

28%

Professor / Associate Prof. 13

11%

Lecturer / Post doc 5

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 79

60%

Biochemistry, Genetics and Molecular Bi... 24

18%

Agricultural and Biological Sciences 18

14%

Chemistry 11

8%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free